Your browser doesn't support javascript.
loading
Phycocyanin as a nature-inspired antidiabetic agent: A systematic review.
Ziyaei, Kobra; Abdi, Fatemeh; Mokhtari, Majid; Daneshmehr, Mohammad Ali; Ataie, Zahra.
Afiliação
  • Ziyaei K; Department of Fisheries, Faculty of Natural Resources, University of Tehran, Karaj, Iran.
  • Abdi F; Non-communicable Diseases Research Centre, Alborz University of Medical Sciences, Karaj, Iran.
  • Mokhtari M; Department of Bioinformatics, Kish International Campus, University of Tehran, Kish Island, Iran; Department of Bioinformatics, Personalized Precision Medicine Institute, Tehran, Iran.
  • Daneshmehr MA; Department of Medicinal Chemistry, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
  • Ataie Z; Evidence-based Phytotherapy & Complementary Medicine Research Center, Alborz University of Medical Sciences, Karaj, Iran; Department of Pharmaceutics, Faculty of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran. Electronic address: zataie@abzums.ac.ir.
Phytomedicine ; 119: 154964, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37544212
ABSTRACT

BACKGROUND:

Nutraceuticals have been important for more than two decades for their safety, efficacy, and outstanding effects. Diabetes is a major metabolic syndrome, which may be improved using nutritional pharmaceuticals. Some microalgae species, such as spirulina, stand out by providing biomass with exceptional nutritional properties. Spirulina has a wide range of pharmacological effects, mostly related to phycocyanin. Phycocyanin is a protein compound with antidiabetic properties, known as a nutraceutical.

OBJECTIVE:

This review delves into phycocyanin applications in diabetes and its complications and ascertains the mechanisms involved.

METHODS:

Scopus, PubMed, Cochrane Library, Web of Science, and ProQuest databases were systematically reviewed (up to April 30, 2023), in which only animal and cellular studies were found.

RESULTS:

According to animal studies, the administration of phycocyanin affected biochemical parameters (primary outcome) related to diabetes. These results showed an increase in fasting insulin serum and a decrease in fasting blood glucose, glycosylated serum protein, and glycosylated hemoglobin. In cellular studies, though, phycocyanin prevented methylglyoxal and human islet amyloid polypeptide-induced dysfunction in ß-cells and induced apoptosis through different molecular pathways (secondary outcome), including activation of Nrf2, PI3K/Akt, and suppression of JNK and p38. Also, phycocyanin exerted its antidiabetic effect by affecting the pathways regulating hepatic glucose metabolism.

CONCLUSIONS:

Thus, based on the available information and literature, targeting these pathways by phycocyanin may unleash an array of benefits, including positive outcomes of the antidiabetic effects of phycocyanin as a nutraceutical. OTHER This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) at the National Institute of Health. The registration number is CRD42022307522.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Secretoras de Insulina / Spirulina Tipo de estudo: Systematic_reviews Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Secretoras de Insulina / Spirulina Tipo de estudo: Systematic_reviews Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article